Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs - A 6-week and a 1-year trial in patients with osteoarthritis

dc.creatorSaag, K
dc.creatorvan der Heijde, D
dc.creatorFisher, C
dc.creatorSamara, A
dc.creatorDeTora, L
dc.creatorBolognese, J
dc.creatorSperling, R
dc.creatorDaniels, B
dc.date2000
dc.dateNOV-DEC
dc.date2014-12-02T16:25:44Z
dc.date2015-11-26T16:19:42Z
dc.date2014-12-02T16:25:44Z
dc.date2015-11-26T16:19:42Z
dc.date.accessioned2018-03-28T23:02:32Z
dc.date.available2018-03-28T23:02:32Z
dc.identifierArchives Of Family Medicine. Amer Medical Assoc, v. 9, n. 10, n. 1124, n. 1134, 2000.
dc.identifier1063-3987
dc.identifierWOS:000165934400029
dc.identifier10.1001/archfami.9.10.1124
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/71199
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/71199
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/71199
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1267727
dc.descriptionIntroduction: Rofecoxib, a cyclooxygenase 2 inhibitor (sometimes known as a specific cyclooxygenase 2 inhibitor or Coxib), is used in osteoarthritis (OA). Published information indicates rofecoxib's improved gastrointestinal safety profile over nonselective nonsteroidal anti-inflammatory agents (NSAIDs). Objective: To evaluate the efficacy and safety of rofecoxib in treating OA in 2 studies. Methods: Two randomized, double-blind, parallel-group studies in patients with OA of the knee or hip were conducted using identical entry criteria and end points. A 6-week placebo-controlled trial in 736 patients compared 12.5 and 25 mg of rofecoxib once daily with 800 mg of ibuprofen 3 times daily, and a 1-year study compared 12.5 and 25 mg of rofecoxib once daily with 50 mg of diclofenac 3 times daily in 693 patients. Results: Rofecoxib, at 12.5 and 25 mg, demonstrated efficacy clinically comparable with ibuprofen, assessed by 3 primary end points according to predefined comparability criteria. Both rofecoxib doses and ibuprofen provided significantly greater efficacy than placebo on all primary end points at 6 weeks. Both rofecoxib doses and diclofenac showed similar efficacy over 1 year. All treatments were well tolerated. Conclusions: Rofecoxib is effective in treating OA with once-daily dosing for 6 weeks and 1 year. Rofecoxib was generally safe and well-tolerated in OA patients for 6 weeks and 1 year.
dc.description9
dc.description10
dc.description1124
dc.description1134
dc.languageen
dc.publisherAmer Medical Assoc
dc.publisherChicago
dc.publisherEUA
dc.relationArchives Of Family Medicine
dc.relationArch. Fam. Med.
dc.rightsfechado
dc.sourceWeb of Science
dc.subjectAntiinflammatory Drugs
dc.subjectClinical-trials
dc.subjectGastrointestinal Toxicity
dc.subjectConsensus Development
dc.subjectMedical-management
dc.subjectKnee
dc.subjectRecommendations
dc.subjectClassification
dc.subjectGastropathy
dc.subjectGuidelines
dc.titleRofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs - A 6-week and a 1-year trial in patients with osteoarthritis
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución